Zila Files Extension for Second Quarter Form 10-Q
12 Marzo 2009 - 9:05PM
Business Wire
Zila, Inc. (Nasdaq:ZILA) today said it has filed an extension on
Form 12b-25 pertaining to the filing of its Form 10-Q for the
second fiscal quarter ended January 31, 2009.
The company is conducting an impairment analysis of its
intangible assets in connection with the Form 10-Q and preparing
additional disclosure regarding the results of this analysis. The
additional time is needed to complete the analysis and related
disclosure. In addition, the analysis and disclosure must be
finalized in order for the company�s independent registered public
accounting firm to complete its review of the Form 10-Q.
The company currently anticipates that its Form 10-Q for the
period ended January 31, 2009 will be filed by March 17, 2009,
within the five-day extension provided under Rule 12b-25(b).
About Zila, Inc.
Zila, Inc., headquartered in Scottsdale, Arizona, is a
diagnostic company dedicated to the prevention, detection and
treatment of oral cancer and periodontal disease. Zila manufactures
and markets ViziLite� Plus with TBlue� (�ViziLite� Plus�), the
company�s flagship product for the early detection of oral
abnormalities that could lead to cancer. ViziLite� Plus is an
adjunctive medical device cleared by the FDA for use in a
population at increased risk for oral cancer. In addition, Zila
designs, manufactures and markets a suite of proprietary products
sold exclusively and directly to dental professionals for
periodontal disease, including the Rotadent� Professional Powered
Brush, the Pro-Select Platinum� ultrasonic scaler and a portfolio
of oral pharmaceutical products for both in-office and home-care
use. All of Zila�s products are marketed and sold in the United
States and Canada primarily through the company�s direct field
sales force and telemarketing organization. The company�s products
are marketed and sold in other international markets through the
direct sales forces of third party distributors. Zila�s marketing
programs reach most U.S. dental offices and include continuing
education seminars for dentists and their staffs.
This press release may contain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are based largely on Zila's expectations
or forecasts of future events, can be affected by inaccurate
assumptions and are subject to various business risks and known and
unknown uncertainties, a number of which are beyond the Company's
control. Therefore, actual results could differ materially from the
forward-looking statements contained herein. A wide variety of
factors could cause or contribute to such differences and could
adversely affect revenue, profitability, cash flows and capital
needs. There can be no assurance that any forward-looking
statements contained in this press release will, in fact, transpire
or prove to be accurate. For a more detailed description of these
and other cautionary factors that may affect Zila's future results,
please refer to Zila's Form 10-K for its fiscal year ended July 31,
2008 and Form 10-Q for the quarter ended October 31, 2008.
For more information about the company and its products, please
visit www.zila.com.
Grafico Azioni Zila (NASDAQ:ZILA)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Zila (NASDAQ:ZILA)
Storico
Da Mag 2023 a Mag 2024
Notizie in Tempo Reale relative a Zila (MM) (NASDAQ): 0 articoli recenti
Più Zila, Inc. Articoli Notizie